Metastatic Colorectal Cancers Withdrawn Phase 2 Trials for Capecitabine (DB01101)

Also known as: Colorectal cancer metastatic / Metastatic Colorectal Cancer

IndicationStatusPhase
DBCOND0063579 (Metastatic Colorectal Cancers)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02085005Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal CancerTreatment
NCT02079220A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal CancerTreatment
NCT00954876Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal CancerTreatment
NCT01293942IXO+A in mCRC With Liver-only MetastasesTreatment